Adjuvant Holdings Co.,Ltd. (TYO:4929)
794.00
+5.00 (0.63%)
At close: Jan 23, 2026
Adjuvant Holdings Revenue
Adjuvant Holdings had revenue of 1.27B JPY in the quarter ending December 20, 2025, with 8.11% growth. This brings the company's revenue in the last twelve months to 3.97B, down -5.23% year-over-year. In the fiscal year ending March 20, 2025, Adjuvant Holdings had annual revenue of 4.10B, down -7.66%.
Revenue (ttm)
3.97B
Revenue Growth
-5.23%
P/S Ratio
1.60
Revenue / Employee
32.01M
Employees
124
Market Cap
6.35B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 20, 2025 | 4.10B | -340.00M | -7.66% |
| Mar 20, 2024 | 4.44B | 61.00M | 1.39% |
| Mar 20, 2023 | 4.38B | -50.00M | -1.13% |
| Mar 20, 2022 | 4.43B | -458.00M | -9.38% |
| Mar 20, 2021 | 4.89B | 211.00M | 4.51% |
| Mar 20, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 20, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 20, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 20, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 20, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Niitaka | 24.16B |
| SHOBIDO | 22.12B |
| Premier Anti-Aging | 15.57B |
| AXXZIA | 14.03B |
| Axas Holdings | 12.45B |
| HABA Laboratories,Inc. | 12.16B |
| Almado | 9.66B |
| Liberta | 9.16B |